Horizon Pharma, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2012 | $66 M | No. 2 | $50 to $250 million | equity, options | SEC | |
| Apr 2010 | $37 M | No. 1 | $10 to $50 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Horizon Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2012).
SEC Form D · Mar 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2012
That is all the official record says: Horizon Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Atlas Venture Associates VI, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Atlas Venture Entrepreneurs Fund VI LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Atlas Venture Fund VI GmbH & Co KG | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Atlas Venture Fund VI LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Essex Woodlands Health Ventures Fund VII LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2011) | SEC Form 3 |
| NGN Biomed Opportunity I Gmbh & Co. Beteiligungs KG | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| NGN BioMed Opportunity I L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Scale Venture Management II, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Scale Venture Partners II, LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 37 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Robert P. De Vaere | Executive officer | Mar 2012 |
| Timothy P. Walbert | Executive officer | Mar 2012 |
| Gino W. Santini | Director | Mar 2012 |
| Jean-Francois W. Formela | Director | Mar 2012 |
| Jeff C. Himawan | Director | Mar 2012 |
| Jeffrey W. Bird | Director | Mar 2012 |
| Louis C. Bock | Director | Mar 2012 |
| Michael W. Grey | Director | Mar 2012 |
| Ronald W. Pauli | Director | Mar 2012 |
| Timothy P. Walbert | Director | Mar 2012 |
| Hubert W. Birner | Director | May 2011 |
| Peter W. Johann | Director | May 2011 |